MabTrix

Company Overview

Snapshot

Founded in December 2015, MabTrix operates with 1–10 employees. The company has secured funding across two rounds from two investors, developing a novel humanized monoclonal antibody for inflammatory bowel disease. MabTrix ceased operations in December 2020.

Business overview

MabTrix is a preclinical-stage biopharmaceutical company focused on developing a function-blocking therapeutic monoclonal antibody (MAb) for inflammatory bowel disease (IBD). Its core technology involves a novel humanized MAb designed to specifically inhibit the enzymatic activity of matrix metalloprotease (MMP) 9 by binding to its catalytic site. The company's technology, licensed from the Weizmann Institute of Science, aims to reduce inflammation in IBD patients and operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, targeting patients and healthcare markets.

Company Intelligence Q&A

What is MabTrix's primary focus?

MabTrix is a preclinical-stage biopharmaceutical company developing a therapeutic monoclonal antibody for inflammatory bowel disease (IBD).

What is the core technology behind MabTrix's therapeutic approach?

MabTrix is developing a novel humanized monoclonal antibody (MAb) that specifically inhibits the enzymatic activity of matrix metalloprotease (MMP) 9 by binding to its catalytic site. This technology was developed at the Weizmann Institute of Science.

When was MabTrix founded?

MabTrix was founded in December 2015.

What is the current operational status of MabTrix?

MabTrix ceased to operate in December 2020.

Which investor participated in MabTrix's funding round in June 2019?

In June 2019, RMGP Biopharma Investment Fund participated in a funding round for MabTrix.